Summary of Recent Deal Activity
- PDF / 56,183 Bytes
- 3 Pages / 586 x 792 pts Page_size
- 66 Downloads / 161 Views
Summary of Recent Deal Activity Diagnostic Technologies Companies 20/20 GeneSystems
Type of deal R&D and licensing agreement
454 Life Sciences
R&D agreement
Affymetrix, Applied Biosystems
Licensing agreement
Affymetrix, Vita Genomics
Licensing agreement
Applied Biosystems, QIAGEN
Licensing agreement
Bruker Daltonik, PanaTecs
R&D agreement
CombiMatrix
R&D agreement
Details 20/20 GeneSystems has acquired exclusive rights from the University of Kentucky to a new blood test that has shown exceptional accuracy for the early detection and screening of non-small cell lung cancer (NSCLC). Working with the team from Kentucky and other leading medical and scientific groups, the company intends to develop a diagnostic that would help identify lung cancer in smokers, former smokers and other at-risk individuals at its earliest, most effectively treatable stages. 454 Life Sciences and the Genome Sequencing Center (GSC) at Washington University School of Medicine in St Louis have initiated a collaborative research plan to sequence disease-causing pathogens and to sequence RNA to analyze gene activity in tissue samples. Research will be performed on 454 Life Sciences’ Genome Sequencer 20 Systems at the GSC. Under the first part of the collaborative research plan, scientists at the GSC and 454 Life Sciences will sequence and analyze the genomes of disease-causing pathogens. By understanding the genomic variations among similar pathogens it is hoped that clinicians may be able to better diagnose, treat, or prevent infections. In a second project, scientists at the GSC, 454 Life Sciences and Washington University School of Medicine will sequence RNA to assess the expression profiles of genes in mammalian cells and tissues. A cell typically uses a fraction of its genes to make proteins at any given time and this selective gene expression results in cells taking on specialized characteristics. The aim is to identify novel drug targets and biomarkers for disease diagnosis. Affymetrix and Applied Biosystems have announced that Applera has taken a nonexclusive, worldwide license to a number of Affymetrix patents related to the manufacture, sale, and use of microarrays for gene-expression analysis. The license will be applied to the continued expansion of the Applied Biosystems Expression Array System for high-density microarray analysis and will enable customers to use that system for gene expression, research and development purposes. Affymetrix has granted Vita Genomics, and its fully owned subsidiary Shanghai GeneCore BioTechnologies, nonexclusive access to Affymetrix microarray technology to develop and market in vitro diagnostic (IVD) tests for alpha interferon treatment response in patients with hepatitis B virus and hepatitis C virus, as well as for early onset and allergic asthma in infants and young children. The resulting microarray-based IVD products would provide clinicians with better diagnosis methods and more efficient approaches for treating patients and managing these diseases. As part of the Powered by Aff
Data Loading...
